Latest Articles

Expert Weighs in on Promising New Options for Frontline Kidney Cancer
BY ANGELICA WELCH
David McDermott, M.D. discusses new advances made to treat kidney cancer. 
FDA Gives Zykadia a Priority Review for Frontline Lung Cancer Treatment
BY JASON M. BRODERICK
The FDA granted Zykadia a priority review for the frontline treatment of some patients with lung cancer.
Personalizing Treatment With ctDNA in Prostate Cancer
BY JASON M. BRODERICK
Since it is found in the majority of patients with mCRPC, circulating tumor DNA may be able to lead the way to more personalized prostate cancer care.
Vyxeos Helps More Patients With AML Proceed to Transplant
BY SILAS INMAN
More people with AML who were treated with Vyxeos were moved to transplant than those treated with a standard chemotherapy regimen, according to recent findings.
Novel Compound Offers Hope in Soft Tissue Sarcoma
BY DANIELLE BUCCO
A phase 2 trial is showing that GPX-150 is promising for patients with soft tissue sarcoma.
Immunotherapy Duo Trumps Single Agent in Metastatic Bladder Cancer
Patients with metastatic bladder cancer who did not see a benefit on single-agent Opdivo did better when the drug was combined with Yervoy, a recent study showed.
Maintenance Revlimid Gains FDA Approval for Multiple Myeloma
BY JASON M. BRODERICK
The Food and Drug Administration (FDA) approved Revlimid (lenalidomide) for maintenance therapy for some patients with multiple myeloma.
Kidney Cancer Trial Recommended to Halt
BY SILAS INMAN
An independent data monitoring committee recommended that the phase 3 ADAPT trial exploring rocapuldencel-T (AGS-003) for the frontline treatment of metastatic renal cell carcinoma (mRCC) be stopped, but Argos Therapeutics explained that they will keep the trial open. 
Improving Survival in Metastatic Pancreatic Cancer
A regimen without gemcitabine had promising survival rates for patients with metastatic pancreatic cancer, according to a recent study.